Pulmonary Fibrosis: What We Have Learnt from Other Tissues
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cell Biology and Pathology".
Deadline for manuscript submissions: closed (31 October 2022) | Viewed by 335
Special Issue Editor
Interests: pulmonary fibrosis; mesothelial cell biology; malignant mesothelioma; post-operative adhesions; cell signalling; macrophage biology; animal models of disease
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
There is a growing interest from the pharmaceutical industry to develop drugs to treat fibrotic diseases. Until recently, diseases such as idiopathic pulmonary fibrosis have had no effective treatments. However, the development of pirfenidone and nintedanib has renewed enthusiasm for developing better drugs that not only slow down the fibrotic response but reverse fibrosis. However, to develop more effective treatments, we first need to better understand disease pathogenesis. There is a growing literature on the pathogenesis of lung fibrosis using cells, tissues and fluids from patients and animal models. There is also a vast amount of data generated from studies examining disease mechanisms in other fibrotic conditions. The focus of this Special Issue will be to examine what we have learnt about the mechanisms driving fibrosis in other tissues and diseases to help us delineate the mechanisms driving fibrosis in the lung.
Dr. Steven E. Mutsaers
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
